[
  {
    "ts": null,
    "headline": "Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma",
    "summary": "RAHWAY, N.J., December 08, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck’s investigational antibody drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), in combination with cyclophosphamide, doxorubicin and prednisone plus rituximab (R-CHP) for the treatment of patients with previously untreated diffuse lar",
    "url": "https://finnhub.io/api/news?id=dc49c9ac09815ab99b0975863395dd1efad8805ab1e8c6866ff546405ae315b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733688000,
      "headline": "Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma",
      "id": 131863350,
      "image": "https://media.zenfs.com/en/business-wire.com/4f0a6a2db8a578331ce193e15d4a4d9a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 08, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck’s investigational antibody drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), in combination with cyclophosphamide, doxorubicin and prednisone plus rituximab (R-CHP) for the treatment of patients with previously untreated diffuse lar",
      "url": "https://finnhub.io/api/news?id=dc49c9ac09815ab99b0975863395dd1efad8805ab1e8c6866ff546405ae315b1"
    }
  }
]